Insight Molecular Diagnostics (IMDX) Depreciation and Depletion (2015 - 2023)

Insight Molecular Diagnostics (IMDX) has 9 years of Depreciation and Depletion data on file, last reported at $404000.0 in Q3 2023.

• Quarterly Depreciation and Depletion rose 3.32% year-over-year to $404000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $1.8 million (up 32.55% YoY) and the FY2022 annual result came in at $1.5 million, up 81.04% from the prior year.
• Depreciation and Depletion retreated to $404000.0 in Q3 2023 per IMDX's latest filing, from $435000.0 in the prior quarter.
• The five-year high for Depreciation and Depletion was $466000.0 in Q4 2022, with the low at -$216000.0 in Q4 2020.
• Average Depreciation and Depletion over 5 years is $209736.8, with a median of $206000.0 recorded in 2021.
• Year-over-year, Depreciation and Depletion sank 427.27% in 2020 and jumped 269.57% in 2021.
• Insight Molecular Diagnostics' Depreciation and Depletion stood at $66000.0 in 2019, then slumped by 427.27% to -$216000.0 in 2020, then soared by 221.3% to $262000.0 in 2021, then surged by 77.86% to $466000.0 in 2022, then retreated by 13.3% to $404000.0 in 2023.
• Business Quant data shows IMDX's Depreciation and Depletion at $404000.0 in Q3 2023, $435000.0 in Q2 2023, and $450000.0 in Q1 2023.